4-(1H-Imidazol-2-YL)butanoic acid | 178388-80-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-(1H-Imidazol-2-YL)butanoic acid
• CAS: 178388-80-2
• 化学式: C₇H₁₀N₂O₂
• mdl: MFCD08668403
• 分子量: 154.17
• InChiKey: AUMHFGPVVAUJHB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.428
• 拓扑面积：
  66
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Substituted imidazole derivatives
  申请人：Wang Weibo

  公开号：US20090258016A1

  公开（公告）日：2009-10-15

  The present invention relates to new substituted imidazole compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds. The compounds of the invention have the following general formula:

  本发明涉及新的取代咪唑化合物及其药学上可接受的盐、酯或前药，以及新化合物与药学上可接受的载体的组合物，和新化合物的用途。本发明的化合物具有以下一般式：
• SUBSTITUTED IMIDAZOLE DERIVATIVES
  申请人：Wang Weibo

  公开号：US20130017196A1

  公开（公告）日：2013-01-17

  The present invention relates to new substituted imidazole compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds. The compounds of the invention have the following general formula:

  本发明涉及新的取代咪唑化合物及其药学上可接受的盐、酯或前药，新化合物与药学上可接受的载体的组合物，以及新化合物的用途。本发明的化合物具有以下一般式：
• Phenoxy derivatives, their preparation, and pharmaceutical compositions containing them
  申请人：YAMANOUCHI PHARMACEUTICAL CO. LTD.

  公开号：EP0130077A2

  公开（公告）日：1985-01-02

  A phenoxy compound represented by general formula (I), or a salt thereof wherein: A is an imidazolyl group, a pyridyl group, a pyridyloxy group, an oxo-substituted chromenyloxy group, a C1-C5 alkyl group, an amino group which may be substituted with a phenyl group or a C1-C5 alkyl group, or a carbamoyl group substituted with a cyclohexylamino group or an imidazolylalkyl group; B is a single bond, a thiazolyl group which may be substituted with a C1-C5 alkyl group, a group represented by formula: -(CH2)n-O-,-(CH2)nCONH(CH2)k-or-(CH2)n-N(R4)-wherein k is 0 or an integer of 1 to 5, n is an integer of 1 to 6 and R4 is a C1-C5 alkyl group; m is 0 or an integer of 1 to 6; R' is a hydroxyl group, an amino group ora C1-C5 alkoxy group; and R2 and R' are the same or different and selected from a hydrogen atom and C,-C5 alkyl groups. The compounds are effective for prophylaxis and treatment of arteriosclerosis, cerebal infraction, transient ischemic attack, angina pectoris, peripheral thrombus and obstruction.

  通式(I)代表的苯氧基化合物或其盐 其中 A 是咪唑基、吡啶基、吡啶氧基、氧代色原氧基、C1-C5 烷基、可被苯基或 C1-C5 烷基取代的氨基、或被环己基氨基或咪唑烷基取代的氨基甲酰基； B 是单键、可被 C1-C5 烷基取代的噻唑基、由式表示的基团：-(CH2)n-O-、-(CH2)nCONH(CH2)k-或-(CH2)n-N(R4)-其中 k 为 0 或 1 至 5 的整数，n 为 1 至 6 的整数，R4 为 C1-C5 烷基； m 为 0 或 1 至 6 的整数； R' 是羟基、氨基或 C1-C5 烷氧基；以及 R2 和 R'相同或不同，选自氢原子和 C,-C5烷基。 这些化合物可有效预防和治疗动脉硬化、脑梗塞、短暂性脑缺血发作、心绞痛、外周血栓和阻塞。
• Heterocyclic compounds, their preparation and, pharmaceutical compositions containing them
  申请人：YAMANOUCHI PHARMACEUTICAL CO. LTD.

  公开号：EP0237138A1

  公开（公告）日：1987-09-16

  A heterocyclic compound selected from those of formula (1), tautomers thereof, and pharmaceutically acceptable salts and esters of formula (I) compounds and tautomers: wherein A represents an alkylene or alkenylene chain which has 1 to 4 carbon atoms and which may have a hetero atom; B, D and Y are selected independently from oxygen and sulfur atoms and NH; R' and R2 are selected independently from hydrogen and halogen atoms and C, to C5 alkyl, C, to C5 alkoxy, C, to C5 alkylthio, phenyl, nitro, hydroxyl, sulfo, imidazolyl-C2 to C5 acylamimo, amino and carboxyl groups; and R3 represents a hydrogen atom, an amino group, a C1 to C5 alkyl group which may be substituted by a carboxyl group, or a phenyl group which may be substituted by a carboxyl, a carboxy-C1 to C5 alkyl, or an imidazolyl-C, to C5 alkylamide group. These compounds, particularly when D is oxygen, are aldose reductose inhibitors useful in treatment of chronic diabetic complications.

  选自式(1)的杂环化合物、其同系物以及式(I)化合物和同系物的药学上可接受的盐和酯： 其中 A 代表具有 1 至 4 个碳原子且可能具有杂原子的亚烷基或烯基链；B、D 和 Y 独立选自氧原子、硫原子和 NH；R'和 R2 独立选自氢原子、卤素原子和 C 至 C5 烷基、C 至 C5 烷氧基、C 至 C5 硫代烷基、苯基、硝基、羟基、磺基、咪唑基-C2 至 C5 氨基酰基、氨基和羧基；R3 代表氢原子、氨基、可被羧基取代的 C1 至 C5 烷基或可被羧基、羧基-C1 至 C5 烷基或咪唑基-C1 至 C5 烷酰胺基取代的苯基。这些化合物，特别是当 D 为氧时，是醛糖还原糖抑制剂，可用于治疗慢性糖尿病并发症。
• Sulfonylbenzyl-substituierte Imidazolylpropensäurederivate
  申请人：BAYER AG

  公开号：EP0557842A2

  公开（公告）日：1993-09-01

  Sulfonylbenzyl-substituierte Imidazolylpropensäurederivate können hergestellt werden, indem man Sulfonylbenzyl-substituierte Aldehyde mit entsprechenden CH-aciden Verbindungen umsetzt und anschließend dehydriert. Die Sulfonylbenzyl-substituierten Imidazolylpropensäurederivate können in Arzneimitteln verwendet werden, insbesondere zur Behandlung von Bluthochdruck und Atherosklerose.

  磺酰基苄基取代咪唑基丙烯酸衍生物可通过磺酰基苄基取代醛与相应的 CH 酸性化合物反应，然后使其脱水来制备。 磺酰基苄基取代咪唑基丙烯酸衍生物可用于制药，特别是用于治疗高血压和动脉粥样硬化。